Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab and ATRA in Relapsed/Refractory Multiple Myeloma
NCT02751255Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2016
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tretinoin in multiple myeloma (MM), sponsored by Amsterdam University Medical Center. Primary endpoints: Maximum Tolerated Dose, Overall Response Rate and 1 more. Started Jul 2016; status: completed.
02
Drugs
tretinoin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02751255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751255.